{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T17:33:11Z","timestamp":1770917591833,"version":"3.50.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T00:00:00Z","timestamp":1770854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:p>This case report describes a canine patient that developed cardiovascular and ocular abnormalities following ingestion of ruxolitinib phosphate 1.5% topical cream. The objective of this report is to characterize the exposure history, clinical presentation, diagnostic findings, therapeutic interventions, and to evaluate ruxolitinib phosphate within the context of its pharmacologic class, emphasizing similarities with related veterinary medications. Building on a recently published retrospective study of oclacitinib maleate overdoses, this case highlights shared clinical manifestations of ruxolitinib phosphate overdose and contributes to a broader understanding of JAK inhibitor toxicosis in veterinary medicine.<\/jats:p>","DOI":"10.3389\/fvets.2026.1757633","type":"journal-article","created":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:45:20Z","timestamp":1770914720000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Clinical manifestations reported in a canine after ingesting ruxolitinib phosphate (Opzelura\u00ae)"],"prefix":"10.3389","volume":"13","author":[{"given":"Leah D.","family":"Swanson","sequence":"first","affiliation":[{"name":"SafetyCall International","place":["Bloomington, MN, United States"]},{"name":"Pet Poison Helpline","place":["Bloomington, MN, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renee D.","family":"Schmid","sequence":"additional","affiliation":[{"name":"SafetyCall International","place":["Bloomington, MN, United States"]},{"name":"Pet Poison Helpline","place":["Bloomington, MN, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Butt","sequence":"additional","affiliation":[{"name":"BluePearl Pet Hospital","place":["Phoenix, AZ, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynn R.","family":"Hovda","sequence":"additional","affiliation":[{"name":"SafetyCall International","place":["Bloomington, MN, United States"]},{"name":"Pet Poison Helpline","place":["Bloomington, MN, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,12]]},"reference":[{"key":"B1","unstructured":"Incyte\n              Corporation\n            \n          \n          Prescribing information: OPZELURA\n          \n          2025"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.3390\/pharmaceutics14051001","article-title":"A comprehensive overview of globally approved JAK Inhibitors","volume":"14","author":"Shawky","year":"2022","journal-title":"Pharmaceutics"},{"key":"B3","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1038\/s41392-021-00791-1","article-title":"The JAK\/STAT signaling pathway: from bench to clinic","volume":"6","author":"Hu","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B4","doi-asserted-by":"publisher","first-page":"3008","DOI":"10.1158\/1078-0432.CCR-11-3145","article-title":"Ruxolitinib: the first FDA approved therapy for the treatment of myelofibrosis","volume":"18","author":"Mascarenhas","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-025-01076-7","article-title":"Multisystemic consequences following oclacitinib maleate (Apoquel\u00ae) overdose ingestion in cats and dogs","author":"Swanson","year":"2025","journal-title":"J Med Toxicol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/vec.13459","article-title":"Oclacitinib intoxication","volume":"35","author":"Lister","year":"2025","journal-title":"J Vet Emerg Crit Care"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2460\/javma.25.04.0240","article-title":"Oclacitinib (Apoquel) toxicosis resulting in acute kidney injury in a dog","volume":"263","author":"Damone","year":"2025","journal-title":"J Am Vet Med Assoc"},{"key":"B8","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40262-023-01225-7","article-title":"Hooge MNL-d, Touw DJ. Pharmacokinetics and pharmacodynamics of ruxolitinib: a review","volume":"62","author":"Appeldoorn","year":"2023","journal-title":"Clin Pharmacokinet"},{"key":"B9","volume-title":"Clinical pharmacology and biopharmaceutics review(s): NDA 202192, ruxolitinib (Jakafi)","year":"2011"},{"key":"B10","unstructured":"Jakavi (ruxolitinib) product monograph and consumer information\n          \n          2020"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.4065\/mcp.2011.0518","article-title":"Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis","volume":"86","author":"Tefferi","year":"2011","journal-title":"Mayo Clin Proc"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.3389\/fonc.2019.01186","article-title":"Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib","volume":"9","author":"Elli","year":"2019","journal-title":"Front Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"2784","DOI":"10.4049\/jimmunol.1200310","article-title":"Inhibition of JAKs in macrophages increases lipopolysaccharide-induced cytokine production by blocking IL-10-mediated feedback","volume":"189","author":"Pattison","year":"2012","journal-title":"J Immunol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-14-3198","article-title":"JAK inhibition impairs NK cell function in myeloproliferative neoplasms","volume":"75","author":"Sch\u00f6nberg","year":"2015","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1111\/jvp.12101","article-title":"Oclacitinib (APOQUEL\u00ae) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy","volume":"37","author":"Gonzales","year":"2014","journal-title":"J Vet Pharmacol Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/jcm11030661","article-title":"Influence of cytokines on inflammatory eye diseases: a citation network study","volume":"11","author":"G\u00e1lvez","year":"2022","journal-title":"J Clin Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/j.1365-2222.2006.02499.x","article-title":"Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures","volume":"36","author":"Leonardi","year":"2006","journal-title":"Clin Exp Allergy"},{"key":"B18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12348-019-0182-y","article-title":"Interleukin-6 inhibition in the management of non-infectious uveitis and beyond","volume":"9","author":"Karkhur","year":"2019","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"B19","volume-title":"Janus kinase (JAK) inhibitors: drug safety communication\u2013FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death","year":"2021"},{"key":"B20","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1002\/joa3.12578","article-title":"COVID-19 induced bradyarrhythmia and relative bradycardia: an overview","volume":"37","author":"Douedi","year":"2021","journal-title":"J Arrhythm"},{"key":"B21","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1161\/CIRCRESAHA.113.300308","article-title":"Adrenergic nervous system in heart failure: pathophysiology and therapy","volume":"113","author":"Lymperopoulos","year":"2013","journal-title":"Circ Res"},{"key":"B22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s13045-023-01471-z","article-title":"Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety","volume":"16","author":"Verstovsek","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1161\/01.ATV.0000029781.31325.66","article-title":"Interrelationships among circulating interleukin-6, C-reactive protein, and traditional cardiovascular risk factors in women","volume":"22","author":"Bermudez","year":"2002","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1080\/00325481.2020.1855921","article-title":"Pathway inhibition and their implications in COVID-19 therapy","volume":"133","author":"Satarker","year":"2021","journal-title":"Postgrad Med"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e11782","DOI":"10.1016\/j.heliyon.2022.e11782","article-title":"Severe ARDS due to ruxolitinib discontinuation syndrome: case presentation and literature review","volume":"8","author":"Houthuys","year":"2022","journal-title":"Heliyon"}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2026.1757633\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T16:45:22Z","timestamp":1770914722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2026.1757633\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,12]]},"references-count":25,"alternative-id":["10.3389\/fvets.2026.1757633"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2026.1757633","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,12]]},"article-number":"1757633"}}